Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1253

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1253
---
ocell Corporation 
     —  
     5,386 

    TOTAL CURRENT LIABILITIES 
     4,083,197  
     6,540,943 

    TOTAL LIABILITIES 
     4,083,197  
     6,540,943 

    COMMITMENTS AND CONTINGENCIES 
     -   

    STOCKHOLDERS’ DEFICIT 

    Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, 0 and 600,000 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     —  
     60 

    Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     —  
     — 

    Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,103,813 and 3,906,300 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     613  
     391 

    Additional paid in capital 
     18,760,320  
     7,074,646 

    Accumulated deficit 
     (21,474,987) 
     (13,519,649)

    TOTAL STOCKHOLDERS’ DEFICIT 
     (2,714,054) 
     (6,444,552)

    TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 
    $1,369,143  
    $96,391 

The
accompanying notes are an integral part of these consolidated financial statements.

F-3 

CHANNEL
THERAPEUTICS CORP

CONSOLIDATED
STATEMENTS OF OPERATIONS

FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023

    Years Ended December 31, 

    2024  
    2023 

    OPERATING EXPENSES 

    General and administrative expenses 
    $4,110,045  
    $2,738